Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

GALAXIES Lung-301 Ph 3 study of Belrestotug and Dostarlimab in 1L Unresectable Locally Advanced/Metastatic PD-L1 Selected NSCLC initiated

June 25, 2024

US FDA puts partial clinical hold on BNT326/YL202 trial

June 25, 2024

Pivotal Ph 2 Trial of Cemacabtagene Ansegedleucel (cema-cel) as 1L Treatment in Large B-Cell Lymphoma (LBCL) patients initiated

June 25, 2024

Recruitment completed for CLINGLIO, the Ph 2b/3 Clinical Trial of idroxioleic acid (LAM561) in combination with RT and TMZ for adults with newly diagnosed GBM

June 18, 2024

Patient Enrollment Completed in Ph 3 Trial Evaluating a Domvanalimab-Containing Regimen in 1L Metastatic Upper GI Cancers

June 18, 2024

IDMC Recommends Continuation of Ph 3 REGAL Trial Without Any Modifications

June 18, 2024

First Patient dosed in Camonsertib Monotherapy NSCLC Expansion of TRESR Clinical Trial

June 18, 2024

First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy

June 18, 2024

Ph 1 clinical trial of Lomonitinib to be initiated in patients with R/R AML 

June 18, 2024

First patient treated with ABBV-383 in CERVINO Ph 3 study in R/R multiple myeloma

June 11, 2024

First patient dosed with BBO-8520 in the Ph 1 ONKORAS-101 trial for KRASG12C NSCLC

June 11, 2024

Ph 1 Trial of Menin Inhibitor HMPL-506 Initiated in Patients with Hematological Malignancies in China

June 11, 2024

Patient Enrollment completed for the Precision-T Ph 3 Study of Orca-T

June 11, 2024

Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

June 4, 2024

Development of IK-930 to be discontinued

June 4, 2024

First Patient Dosed in Ph 1 Clinical Study of SOT201 for Patients with Solid Tumors

June 3, 2024

First Patient Enrolled in AFFIRM-205, a Ph III Study of LAE002 (afuresertib) + Fulvestrant for Treatment of Breast Cancer

June 3, 2024

First Patient Dosed in trial Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC

June 3, 2024

First Patient Dosed in KRAS G12V Ph 1 Program

June 3, 2024

First Patient Dosed in Global Tumor-Agnostic Ph 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors

June 3, 2024

First Patient Dosed in Ph 1/2 Clinical Trial of TSN1611

May 29, 2024

Development of TNG348 program to be discontinued

May 29, 2024

First Patient dosed in Ph 1 Trial of GIGA-564 in Advanced Solid Tumors

May 29, 2024

First Patients Dosed in Ph 2a Study of BTX-A51 in Genetically-Defined Breast Cancer

May 29, 2024

First Patient Dosed in Randomized Ph 2 Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

May 29, 2024
Page1 … Page8 Page9 Page10 Page11 Page12 … Page22

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.